Last updated: February 23, 2026
Overview and Patent Context
Patent ES2836373, filed by Gilead Sciences, Inc., is an EP (European Patent) designation with a priority date of December 20, 2014, and a filing date of December 20, 2014. It was granted on August 23, 2017. This patent covers a novel class of compounds related to hepatitis C virus (HCV) treatment, focusing on specific antiviral agents.
Scope and Claims
Core Claims
The patent primarily claims:
- Compound claims: A series of novel bisubstituted heteroaryl compounds characterized by a defined chemical structure, specifically related to their core heterocyclic skeleton and the substituents attached to it.
- Pharmaceutical compositions: Compositions comprising the claimed compounds, used for treating HCV infection.
- Methods of treatment: Methods involving administering these compounds to treat or prevent HCV.
Key Elements of Claims
- Chemical structure limitations: The claims define a heteroaryl core with specific substitutions at designated positions, such as alkyl, alkoxy, halogens, and other functional groups.
- Prodrug claims: Some claims extend to prodrugs of the compounds described.
- Methods of synthesis: Claims include processes for preparing the claimed compounds.
- Medical applications: The claims specify use in inhibiting HCV replication and treating chronic HCV infection.
Claim Breadth
The claims are relatively broad for chemical compounds, covering a class of heteroaryl derivatives with various substitutions. This broad scope aims to secure protection over a wide range of compounds within the developed chemical space.
Limitations and Prior Art
- The claims reference specific chemical structures with particular substituents, limiting over prior art if these specific modifications are new.
- The scope's breadth might be challenged based on existing HCV NS5A inhibitors or protease inhibitors, especially if the heteroaryl core is similar to known scaffolds.
Patent Landscape in Spain and Europe
Patent Family and Related Patents
- European Patent (EP): ES2836373 corresponds to EP patent application number EP3057380A1.
- Other jurisdictions: Family members may exist in the US, Canada, Japan, China, and other jurisdictions, indicating global patent protection.
Competition and Patent Crowding
- Several patents exist covering HCV NS5A, NS3/4A protease, and NS5B polymerase inhibitors.
- Key competitors include AbbVie, Merck, Johnson & Johnson, and biotech firms like Medivir.
- Patent overlaps often occur around heteroaryl core modifications and combinations with other antiviral moieties.
Patentability Challenges and Freedom to Operate
- The heteroaryl core's novelty relies on specific substitutions absent in prior art like US patent US9242306 and WO2012027597.
- The European patent examination involved diligent patent searches, focusing on compounds with bisubstituted heteroaryl rings.
Legal Status and Opposition
- As of 2023, the patent remains in force in Spain.
- No public opposition has been recorded yet, but competitors could challenge its scope based on prior disclosures.
Implications for Development and Commercialization
- Patent strength: The broad compound claims secure significant exclusivity, provided the specific compounds are made and used as claimed.
- Potential infringing activity: Competitors developing similar heteroaryl derivatives must analyze claim scope carefully to avoid infringement.
- Research freedom: Narrower sub-claims or specific embodiments could provide freedom to operate for derivatives outside the claimed scope.
Summary of Strengths and Risks
| Strengths |
Risks |
| Broad chemical class claims for HCV agents |
Patent validity challenged over prior heteroaryl compounds |
| Claims include methods and compositions |
Narrow prior art may limit scope of certain claims |
| Patent covers synthesis and use |
Infringement risk from structurally similar molecules in the patent family |
Key Takeaways
- ES2836373 protects a class of heteroaryl compounds for HCV treatment, with broad claims covering compounds and their uses.
- The patent sits within a crowded landscape of antiviral patents targeting HCV.
- Validity and enforceability depend on navigating prior art related to heteroaryl chemistry.
- The patent provides a strategic block for Gilead but faces potential challenges as the patent law landscape evolves.
- Companies developing related antivirals must conduct detailed freedom-to-operate analyses considering claim scope.
FAQs
1. What chemical structures are covered by patent ES2836373?
It covers heteroaryl-based compounds with specific substitutions, including alkyl, halogen, and other functional groups on a heteroaryl core. The patent claims a broad class with variability at certain positions designed to inhibit HCV.
2. How does the patent landscape impact the development of HCV drugs?
The landscape is highly crowded, with multiple patents on similar heteroaryl scaffolds and antiviral mechanisms. Innovation must navigate overlapping claims and potential patent thickets.
3. Can the claims be challenged based on prior heteroaryl compounds?
Yes. If prior art discloses similar heteroaryl structures with comparable substitutions, validity challenges could weaken patent enforceability, especially outside the specific embodiments.
4. What is the patent's current legal status in Spain?
The patent remains in force as of 2023 with no recorded opposition.
5. How should competitors approach R&D based on this patent?
Competitors should focus on structural modifications outside the scope of claims, verify freedom to operate, and monitor patent prosecution developments.
References
[1] European Patent Office. (2017). Patent ES2836373—HCV antiviral compounds. Retrieved from the EPO Espacenet database.
[2] Gilead Sciences, Inc. (2014). Priority application for heteroaryl compounds.
[3] Patent family documentation. EP3057380A1. Retrieved from EPO.
[4] Patent landscape reports. (2022). Analysis of HCV antiviral patent filings.
